Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

AXLA - Axcella Health Inc.

Close
4.58
-0.900   -19.651%

Share volume: 41,958
Last Updated: Wed 22 Nov 2023 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): 35.29%

PREVIOUS CLOSE
CHG
CHG%
$5.48
-0.90
-16.42%
This ticker is disabled and data are no longer maintained and up to date.
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 25%
Dept financing 8%
Liquidity 50%
Performance 15%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$4.58
P/E Ratio 
0.00
DAY RANGE
$4.58 - $4.58
EPS 
$0.00
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
2.948 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO: William R. Hinshaw
Region: US
Website: axcellahealth.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction of risk of overt hepatic encephalopathy recurrence.

Recent news